OptiPharm Co

OptiPharm Co FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of OptiPharm Co (153710.KQ) as of Nov 2, 2026 is 164.03 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 98.94 % — a change of 65.79% (higher).

FCF Conversion

164.03 %

YoY

65.79%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of OptiPharm Co is 2025 164.03 % . FCF Conversion Rate (FCF/EBITDA) of OptiPharm Co was 2024 98.94 % . It decreases by 65.79% higher compared to the previous year.

The OptiPharm Co FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
-165.51 KRW
Jan 1, 2019
27.31 KRW
Jan 1, 2020
106.59 KRW
Jan 1, 2021
88.55 KRW
Jan 1, 2022
344.23 KRW
Jan 1, 2023
141.99 KRW
Jan 1, 2024
98.94 KRW
Jan 1, 2025
164.03 KRW
The OptiPharm Co FCF Conversion history
YEARFCF ConversionYoY
164.03 %+65.79%
98.94 %-30.32%
141.99 %-58.75%
344.23 %+288.76%
88.55 %-16.93%
106.59 %+290.26%
27.31 %-116.50%
-165.51 %-733.34%
26.13 %-119.37%
-134.90 %-434.41%
40.34 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

OptiPharm Co Stock analysis

What does OptiPharm Co do? OptiPharm Co Ltd generates revenue through its Sale Business segment, which provides livestock disease appraisal services, distributes animal drugs, and manufactures and sells feed additives. The New Business segment develops heterologous organisms, VLP vaccines, and human diagnostic kits, including heterologous skin, xenogeneic islets, and xenogeneic corneal products, as well as VLP-based animal combined vaccines and HPV vaccines for humans. Human diagnostic kits target breast and cervical cancer reagents. Products are distributed domestically and internationally, serving both local and overseas markets. The company's primary customers are domestic and international buyers of pharmaceuticals, livestock health products, and diagnostic solutions. The Sale Business segment caters to agricultural and veterinary sectors, while the New Business segment serves healthcare providers and diagnostic laboratories. Revenue streams include product sales from both segments, with a focus on high-demand medical and animal health solutions. OptiPharm Co Ltd's business model relies on manufacturing and wholesaling pharmaceuticals, with the Sale Business segment emphasizing livestock health services and animal drug distribution, and the New Business segment focusing on innovative medical technologies. The firm's product portfolio spans from feed additives to advanced diagnostic kits, targeting both domestic and global markets for sustainable growth. OptiPharm Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OptiPharm Co stock

FCF Conversion Rate (FCF/EBITDA) of OptiPharm Co is 164.03 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of OptiPharm Co changed from 98.94 % to 164.03 %, representing a 65.79% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) OptiPharm Co since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s OptiPharm Co with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — OptiPharm Co

All Key Metrics — OptiPharm Co